The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...

Coming off of Novo Nordisk's (NVO) sharp stock decline after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted, BMO Capital Markets ...

Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...

Henrik Wulff, the man in charge of product supply at Novo Nordisk, just spent $11 billion to try to fill an ocean. Novo has ...

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...

Novo Nordisk and Eli Lilly are currently a duopoly in the obesity market, which reached a value of $24 billion last year ...

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

U.S. retail investor fund flows into Novo Nordisk surged 32-fold on Friday, as the Danish drugmaker's weaker-than-expected ...

Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...

MDGL), could bode well for Novo Nordisk A/S (NYSE: NVO). The pharma industry giant has seen explosive sales growth for its GLP-1 agonist drug, semaglutide. Marketed through the names Ozempic and ...

Novo Nordisk ( NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't ...

The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...